Mark Asset Management LP Moderna, Inc. Transaction History

Mark Asset Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$96.41 - $126.61 $2.55 Million - $3.35 Million	-26,471 Reduced 62.91%	15,604 $1.61 Million
Q2 2023 Aug 14, 2023	SELL	$118.5 - $160.53 $50,362 - $68,225	-425 Reduced 1.0%	42,075 $5.11 Million
Q1 2023 May 15, 2023	SELL	$135.66 - $197.02 $258,296 - $375,126	-1,904 Reduced 4.29%	42,500 $6.53 Million
Q4 2022 Feb 14, 2023	BUY	$118.38 - $210.04 $4.07 Million - $7.23 Million	34,404 Added 344.04%	44,404 $7.98 Million
Q2 2022 Aug 15, 2022	BUY	$117.13 - $176.59 $1.17 Million - $1.77 Million	10,000 New	10,000 $1.43 Million
Q1 2022 May 16, 2022	SELL	$126.46 - $235.05 $3.45 Million - $6.41 Million	-27,264 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$225.82 - $368.51 $5.39 Million - $8.8 Million	-23,871 Reduced 46.68%	27,264 $6.93 Million
Q3 2021 Nov 15, 2021	SELL	$221.9 - $484.47 $934,199 - $2.04 Million	-4,210 Reduced 7.61%	51,135 $19.7 Million
Q2 2021 Aug 16, 2021	BUY	$129.91 - $234.98 $3.6 Million - $6.51 Million	27,714 Added 100.3%	55,345 $13 Million
Q1 2021 May 17, 2021	BUY	$109.18 - $185.98 $3.02 Million - $5.14 Million	27,631 New	27,631 $3.62 Million

954

241M

10.6M

18.7M

Ticker MRNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 391,200,000
Market Cap $14.4B
Description
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...

Get notified when there are updates to the investment portfolio of Mark Asset Management LP, based on Form 13F filings with the SEC.

Stay updated on Mark Asset Management LP with notifications on news.